FIELD: medicine.
SUBSTANCE: group of inventions relates to the treatment of Parkinson's disease. Following is disclosed: 1) a method of treating Parkinson’s disease in an individual in need thereof, comprising administering to said individual a parenteral composition containing carbidopa and levodopa, wherein said parenteral composition is prepared for subcutaneous administration and it is administered essentially continuously, and an oral composition comprising entacapone, wherein said oral composition contains about 400, 450, 500, 550 or 600 mg of entacapone and is administered two or three times a day; and 2) corresponding use of a combination of carbidopa, entacapone and levodopa.
EFFECT: significant (from 420 to 620 ng/ml) increase in the level of levodopa in the blood of patients without significant fluctuations.
21 cl, 6 dwg, 18 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CONTINUOUS ADMINISTRATION OF L-DOPA, DOPA DECARBOXYLASE INHIBITORS, CATECHOL-METHYLTRANSFERASE INHIBITORS AND INTENDED FOR THIS COMPOSITION | 2011 |
|
RU2740080C2 |
| CONTINUOUS ADMINISTRATION OF L-DOPA, INHIBITORS OF DOPA-DECARBOXYLASE, INHIBITORS OF CATECHOL-O-METHYLTRANSFERASE AND COMPOSITIONS, INTENDED FOR IT | 2011 |
|
RU2607497C2 |
| COMPOSITIONS FOR CONTINUOUS CONTROL OF DOPA-DECARBOXYLASE INHIBITORS | 2010 |
|
RU2559083C9 |
| COMPOSITIONS FOR CONTINUOUS ADMINISTRATION OF DOPA-DECARBOXYLASE INHIBITORS | 2010 |
|
RU2678839C2 |
| DOPA DECARBOXYLASE INHIBITOR COMPOSITIONS | 2015 |
|
RU2684105C2 |
| PHARMACEUTICAL COMPOSITIONS FOR TREATING PARKINSON'S DISEASE | 2009 |
|
RU2540470C9 |
| METHODS OF PARKINSON'S DISEASE TREATMENT | 2004 |
|
RU2342929C2 |
| COMT INHIBITOR DOSAGE REGIMEN | 2007 |
|
RU2518483C2 |
| SCHEDULE OF NITROCATECHOL INTRODUCTION | 2009 |
|
RU2557532C2 |
| COMBINATIONS CONTAINING mGluR MODULATORS FOR TREATING PARKINSON'S DISEASE | 2009 |
|
RU2496494C2 |
